Novacyt S.A. (NVYTF) Q4 2024 Earnings Call Transcript
2025-05-02 16:11:05 ET
Novacyt S.A. (NVYTF)
Q4 2024 Results Conference Call
April 30, 2025 06:00 AM ET
Company Participants
Lyn Rees - Chief Executive Officer
Steve Gibson - Chief Financial Officer
Presentation
Operator
Good morning, and welcome to the Novacyt Full Year Results Investor Presentation. [Operator Instructions] Before we begin, I'd like to do the following poll. For the benefit of those joining us from France [Foreign Language].
I'd now like to hand you to Lyn Rees, CEO. Good morning to you, sir.
Lyn Rees
Good morning, and thank you, and good morning, everyone. We really appreciate you joining us today, and we look forward to giving you the latest update from the Novacyt Group. Presenting today is myself, Lyn Rees, Chief Exec; and Steve, our CFO.
And we're just about to celebrate our 1-year anniversary of being the CFO and CEO of this business. A lot has happened over the last 12 months, and we look forward to sharing that with you today.
As you know, the Novacyt Group is an international molecular diagnostics company, and we're fundamentally split into 2 key areas. We've got the acquired Yourgene Health business, which focuses on clinical IVD-approved assays and DNA site selection through our range of technology. And then we have our Primerdesign business, which is our research or research use-only products fundamentally in qPCR format that we take out to the global market. Between the 2 businesses, we cover human health, reproductive health, precision medicine, infectious disease and then nonhuman applications such as veterinary, animal, food, water and plant.
In terms of the business today, rather than talk through some words, I realize that a lot of you shareholders are probably not aware of where the business is situated or what the business looks like, so we created a short video. And Alessandro, if you could just press play on that, please, on the next slide, and then I'll talk through the video to give you an idea of who we are as an organization and where we currently live....
Read the full article on Seeking Alpha
For further details see:
Novacyt S.A. (NVYTF) Q4 2024 Earnings Call TranscriptNASDAQ: NVYTF
NVYTF Trading
-88.03% G/L:
$0.48 Last:
100 Volume:
$0.48 Open:



